四度无缘谈判桌,“天价抗癌药”纳入医保为何难

第一财经
25 Nov 2024

新版国家医保药品目录预计于本周内揭晓,但四款CAR-T(嵌合抗原受体T细胞免疫疗法)产品“败北”已是既定事实。   CAR-T疗法已第四年无缘医保谈判桌,业界对于这一结果早有预判:年治疗费用动辄百万,与“国谈”中“五十万不谈,三十万不进”的隐形门槛相距甚远,国外已逐渐成熟的商保按疗效付费、分段付费的逻辑,似乎也难以迁至基本医保付费的场景中。   生产企业的“屡败屡战”,彰示着其始终渴望医保内市场。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10